Brought to you by 
Fate Therapeutics gets IP from two tech transfers
23 Apr 2020
Executive Summary
Fate Therapeutics (stem cell technology) has licensed exclusive rights to intellectual property jointly owned by Children's Hospital Boston and Massachusetts General Hospital pertaining to compositions and methods of supporting hematopoietic stem cells.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fate Therapeutics gets IP from two tech transfers
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice